Skip to main content

Celgene To Buy Juno Therapeutics For Approximately $87 Per Share In Cash

Celgene Corporation and Juno Therapeutics announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.